Videos Documenting Functional Change Following
NVG-291 Treatment in the CONNECT SCI Study
The videos below present visual documentation from the CONNECT SCI Study showing participants performing a standardized
10-meter walking assessment at baseline and after 12 weeks of NVG-291 treatment. These side-by-side recordings highlight the functional impact of NVG-291 treatment, including observable changes in gait, balance, coordination, and walking efficiency
NervGen Pharma Corp (“NervGen”) (TSXV: NGEN) (OTCQB: NGENF), is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic disorders. NervGen’s lead candidate, NVG-291, is a first- and potential best-in-class candidate being evaluated in the Phase 1b/2a CONNECT SCI Study in individuals living with spinal cord injury.
Contact
112-970 Burrard Street
Unit 1290
Vancouver, BC V6Z 2R4
Phone: (778) 731-1711
Email: [email protected]